Oncolytics Biotech is engaged in the discovery and development of pharmaceutical products, namely REOLYSIN® for the treatment of cancers that have not been successfully treated with conventional therapeutics. The product being developed by Co. may represent a novel treatment for Ras mediated cancers which can be used as an alternative to existing cytotoxic or cytostatic therapies, as an adjuvant therapy to conventional chemotherapy, radiation therapy, or surgical resections, or to treat certain cellular proliferative disorders for which no current therapy exists.